Devonian Health Group Inc. (Devonian or the Corporation) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announced today that it has formed a Scientific Advisory Board comprised of experts in botany, chemistry, immunology, infectious diseases, drug discovery and development. This Scientific Advisory Board will assist Devonians Research and Development team in the development of cannabino¯ds-based pharmaceutical drugs.
The appointees are Dr. Louis Flamand, PhD, MBA (Laval University), Dr. Suha Jabaji, PhD (McGill University), Prof. Francois Malouin, PhD (Universit de Sherbrooke), and Dr. John Trant, PhD (University of Windsor).
We are honored to welcome these leading Canadian experts to our new Scientific Advisory Board. The expertise they bring to our team will be invaluable in guiding us through the development of cannabinoids-based pharmaceutical drugs, said Dr. Andr P. Boulet, PhD., President & CEO of Devonian.
We believe that cannabinoids-based products could be developed as pharmaceutical drugs either under the normal drug development pathway, as New Chemical Entities (NCE) or under the Botanical Drug Regulation. Under the Botanical Drug Regulation, plant materials, algae, macroscopic fungi, or combinations thereof can be developed as a prescription drug1. Such products benefit of the combined effects of the components called the ˜˜entourage effects. The botanical drugs special features require consideration and adjustment during regulatory review process. The US-Food and Drug Administration (FDA) issued a Guidance for Industry-Botanical Drug Products1 to take into consideration these features and to facilitate development of new prescription medicines from botanical sources. Devonians core strategy is to develop drugs, including cannabino¯ds, within the Botanical Drug Regulatory pathway., added Dr Boulet.
The Corporation also announces the filing of an application in order to obtain a Cannabis Research Licence from Health Canada.
Dr Louis Flamand, PhD, MBA
Louis Flamand, PhD, MBA, is a full professor and chair of the department of microbiology-infectious-disease-immunology at the Faculty of medicine, Universit Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research center-Universit Laval. Before joining Laval university, Dr Flamand obtained his PhD in virology from the University of Montreal and post-doctoral training that the National Institutes of Health and at the Institute of Human Virology (Maryland, USA). He received his MBA in pharmaceutical management from Universit Laval. He is also member of the HHV-6 Foundation scientific advisory board since 2006. Dr Flamand has experience in pre-clinical development. Throughout his career, Dr Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology. Dr Flamand is the author of more than 90 peer-reviewed publications and is lead Editor of the book Human Herpesviruses HHV-6A, HHV-6B & HHV-7: Diagnosis and Clinical Management 3rd edition.
Dr Suha Jabaji, Ph.D.
Dr Suha Jabaji, PhD. is a molecular plant pathologist in training. She obtained her PhD from the University of Waterloo, Ontario, Canada. At the rank of full Professor in Plant Science, McGill University, her scientific contributions are recognized at the national and international levels. She has published 90 plus-refereed scientific reports and delivered more than 200 scientific presentations at scientific conferences. The creativity, relevance, and significance of her research results impacting sustainable agriculture is recognized by invitations to speak in symposia and conference presentations at scientific meetings, and serving on national and international editorial boards and grant panels. Her research expertise focuses on functional genomics and metabolomics of plant fungal pathogens and beneficial microbes that boost the plants immune system against biotic and abiotic stress has attracted International researchers to spend time in her lab for training. Her research program is funded by provincial, federal grants as well as industrial collaborative grants and contracts. She has mentored more than 100 graduate and postgraduate students in the field of Plant-microbe interactions. Among her current research themes is the development of effective antimicrobials for the hemp and Cannabis industries, and understanding their mode of action in order to increase their efficiencies. Between 2005-2015, she was appointed as the Associate Dean of Research and Graduate Education of the Faculty of Agricultural and Environmental Sciences (FAES), McGill where she oversaw the research activities of more than 90 staff at FAES. She currently serves as Past-President of the International Rhizoctonia Subject Matter Committee whose mandate is to coordinate international effort towards effective communication among scientists working on the economic soilborne fungal pathogen Rhizoctonia and promote exchange of resources and ideas among scientists.
Prof Fran§ois Malouin, PhD
Fran§ois Malouin is professor (microbiology) at the Department of biology at the Faculty of sciences of Universite de Sherbrooke since 2000. He is a microbiologist that has more than 30 years of academic and industrial experience in drug discovery for use in humans and food-producing animals. Prof Malouin obtained a doctoral degree (Ph.D.) in Medical Sciences (Medical Microbiology) at the University of Calgary (1988) and did postdoctoral training in the anti-infective research group at Lilly Research Laboratories (Eli Lilly & Co., Indianapolis, USA) from 1988 to 1990. Prof Malouin was also Assistant professor of microbiology at the Faculty of medicine of Universit Laval in Quebec City where he had a Fellowship from the Medical Research Council of Canada (1990-1994). He was then recruited by biotechnology companies, first Microcide Pharmaceuticals, Inc., then a sister company, Iconix Pharmaceuticals, Inc. (Silicon Valley, California, USA) from 1994 to 2000, where he was Associate Director of technology development for the discovery of new therapeutic targets and antibiotics. He was also a co-founder of Ulysses Pharmaceuticals (Sherbrooke, QC). Currently at U. de Sherbrooke, his research projects aim at exploiting virulence genes for the development of new antibiotics, vaccines and non-antibiotic alternatives for applications in human and animal health. He is co-author of >100 scientific publications and co-inventor of more than 20 patents (delivered or pending). ). Prof. Malouin was a member and president of the institutional patent committee at Universit de Sherbrooke from 2009 to 2017.
Medicinal plants have been used for centuries for treating various types of illnesses including treatment of infectious diseases. A richness of new chemical entities remains unexploited to this day and cannabinoid-rich products represent such an untapped source of bioactive phytomolecules to address the current crisis of antibiotic resistance. Said Prof Malouin.
Dr John Trant, PhD
Dr. John Trant received his PhD from the University of Ottawa in 2012 in making antifreeze glycopeptides under the supervision of Dr. Robert Ben. After postdoctoral work with Dr. Tomas Hudlicky (natural product synthesis, Brock) and Dr. Elizabeth Gillies (polymer and nanoscience, Western) he began his own group at the University of Windsor in 2016. The Trant group is focused on bringing the tools of synthetic chemistry to bare on unsolved problems in biomedicine and materials science. The group has active research in molecular and microbiology, natural product and peptide synthesis, and computational chemistry and biochemistry. The group conducts interdisciplinary research with collaborators from around Canada and the World in drug development, analytical chemistry, computational chemistry as well as leading research programs in undergraduate research pedagogy, and laboratory safety. The group has attracted over $2 million in research and infrastructure funds in the first three years of the lab, and currently comprises seven post-doctoral fellows, five graduate students and thirty-one undergraduate researchers.
˜We are exceptionally excited to move forward in this collaboration with Devonian Health Group to advance the health of Canadians. Said Dr Trant.
Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonians focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Qubec, Canada where it owns a state-of-the art extraction facility with full traceability ˜from the seed to the pill. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).
For more information, visit www.groupedevonian.com.
1. Botanical Drug Development, Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), December 2016.
Forward Looking Statements
This press release contains forward-looking statements about Devonians objectives, strategies and businesses that involve risks and uncertainties. These statements are forward-looking because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonians ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonians prospectus dated April 21st, 2017 under the heading Risk Factors related to Devonians business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Dr André P. Boulet, PhD
President and Chief Executive Officer
Health Group inc.
Telephone: (514) 248-7509
Email: [email protected]m
Long-Term Damage Happening to Canada’s Airlines: CUPE
Monday’s financial update from Ottawa provided no support for Canada’s struggling airlines.
CUPE local 4070 represents 4,100 cabin crew members at WestJet and its affiliates. The union joined business, industry experts and others this week in sounding the alarm about the future of Canada’s airlines.
After months of inaction, Canada remains the only G7 country with no relief package for airlines,” said CUPE 4070 President Chris Rauenbusch.
“Our voices are raw from screaming about this issue: if the Liberals don’t do something immediately, Canada will be without airlines.” Rauenbusch said the Liberal approach of prioritizing regional service above all is the wrong approach. Rauenbusch said regional service thrives when airlines have thriving networks to connect to.
“Viewing regional service in isolation simply won’t work.”
Canadas airlines are losing market-share to well-supported carriers from around the world,” said Rauenbusch. “Over 100,000 Canadians employed by airlines are waiting for action, and we’re not seeing anything.
In a statement this week, the National Airlines Council of Canada (NACC) said, This lack of action does not reflect the economic importance of the sector to Canada’s overall recovery, nor the need to ensure Canada’s largest carriers can continue to compete internationally.
“If the Liberals keep ignoring the airline sector, we will never return to work,” said Rauenbusch. “And Canadians will travel on foreign carriers supported by foreign governments. This is not how we return our country to stability.
Protegrity Partners With Servian, Expanding Global Reach in Australia and New Zealand
Protegrity, the data-security solutions provider, has partnered with Servian, one of Australias leading IT consultancies, to deliver effective data protection to companies across Australia and New Zealand (ANZ) that are implementing AI, analytics, customer engagement, and cloud solutions. A primary objective for Protegrity and Servian is securing data for companies using Snowflake, a cloud data platform provider and Protegrity partner. Snowflake has grown rapidly in the ANZ market and its partnership with Protegrity enables customers to deploy Protegrity’s data de-identification technology to protect any data housed in Snowflake’s managed cloud data warehouse. Servian and Protegrity will also work with joint customers to ensure compliance with evolving data privacy regulations and uphold the privacy of individuals while empowering companies to unlock the full potential of their data.
Protegritys data protection offerings are closely aligned with our mission to enable customers to use data and analytics to further establish their competitive advantage, said Tristan Sander, Partner at Servian. We look forward to working with Protegrity to deliver market-leading data security solutions to our customers.
Protegrity has witnessed a growing demand for data security solutions in ANZ as companies in the region have become increasingly mindful of how they manage their data and comply with GDPR and other codified expectations “ including the Australian Privacy Principles Act and the Asia Pacific Economic Cooperation (APEC) Cross Border Privacy Rules (CBPR) “ to protect customer privacy. The prominent expansion of Snowflake in ANZ has also contributed to Protegritys visibility in the region. Protegrity for Snowflake provides the control businesses need to protect data in the cloud beyond encryption and data masking. With Protegrity’s format-preserving data protection, data and analytics professionals can perform analytics directly on de-identified data without having to unprotect or re-identify the data.
Weve seen an increasing demand from companies in the ANZ region who are implementing AI, analytics, and cloud technologies, said Protegrity President and CEO Rick Farnell. Protegrity is purpose-built for hybrid-cloud and multi-cloud environments and our proven data-protection capabilities enable businesses to extract intelligence-driven insights from their most sensitive data and deliver better customer experiences. Together, Protegrity, Servian, and Snowflake are embarking on a journey to safely accelerate the democratization of data, allowing our mutual customers to further their innovation while protecting sensitive data “ no matter where it resides.
Register today for an on-demand webinar with Protegrity, Servian, and Snowflake to learn how this partnership gives companies the confidence to use and share data across business lines while reducing the risk of breaches of sensitive data.
Protegrity, a global leader in data security, protects sensitive data everywhere and future-proofs businesses as data-privacy regulations evolve. Maintaining privacy today across distributed data has become impossibly complicated. With Protegrity, enterprises can secure data wherever it resides, control how its protected, and have confidence that data is safe, even if a breach occurs. The Protegrity Data Protection Platform is a modern alternative to traditionally complex data-protection methods that leave gaps in security. Whether encrypting, tokenizing, or applying privacy models, Protegrity protects data at the speed of business. Deep integrations with Snowflake, Amazon Redshift, Teradata, Oracle, Microsoft SQL Server, Cloudera, Databricks, and many other enterprise applications ensure that data remains fully protected in hybrid-cloud, multi-cloud, and on-premises environments without performance penalties. The platforms fine-grained data protection anonymizes personally identifiable information (PII) thats used in AI and machine learning models, providing faster access to critical analytics data and dramatically shortening the time to business insights. Protegrity protects the sensitive data of over one billion individuals across global enterprises, including five of the worlds 40 largest banks, five out of 10 of the top health insurance providers, and three of the worlds leading multinational companies. With more than two decades of industry-leading innovation, Protegrity allows businesses to finally tap into the value of their data and accelerate digital transformation timelines “ without jeopardizing individuals fundamental right to privacy.
Bhava Communications for Protegrity
To Help Fleet Customers Make the Switch to Electric Vehicles, PG&E Introduces EV Fleet Savings Calculator
Today, Pacific Gas and Electric Company (PG&E) announced a new online tool for companies and organizations considering transitioning their fleets to electric vehicles (EVs). PG&Es new EV Fleet Savings Calculator allows business customers and public agencies with medium- to heavy-duty fleet vehicles to explore EV investment estimates based on their own fleet sizes, infrastructure, budget and other factors.
Transportation is the single largest source of climate-related pollution in California, contributing to 41% of greenhouse-gas emissions across the state. Heavy- and medium-duty vehicles often use diesel, which is a highly polluting fuel. EVs are four times more efficient than diesel and natural gas engines and offer significant fuel cost savings.
Expanding the use of electric vehicles is essential for California to achieve its bold climate and clean-air goals. PG&E has been an active partner in helping make EVs an option for millions of Californians, including for our business and public agency customers who are transitioning their fleets to electric vehicles. Reducing vehicle emissions is good for our state and good for the environment in which we all live,” said PG&E Corporation Interim CEO Bill Smith.
PG&Es own commitment to further electrify its vehicle fleet by 2030 includes 100% of its light-duty fleet, 10% of its medium-duty fleet and 5% of its heavy-duty fleet.
In addition to the new EV Fleet Savings Calculator, PG&E offers business and public agency customers innovative rate options as well as its EV charging infrastructure program for fleets.
PG&Es New Tool for Electrifying Medium- and Heavy-Duty Fleet Vehicles
For customers with fleets that are making the transition to electric, an essential step in the process is understanding the costs and potential cost savings when deploying EVs. PG&Es new EV Fleet Savings Calculator, using calculations based on PG&Es new Business EV Rate, allows business and public agency customers to evaluate their fleet plans by analyzing how much they can save by switching to EVs.
The tool helps customers better understand key total cost of ownership factors including incentives, energy costs, infrastructure considerations and participation in Californias statewide Low Carbon Fuel Standard (LCFS). After customers input information on vehicles and usage, the tool offers recommendations for charging infrastructure, charging schedule based on fleet needs, how much they can save on fuel costs, revenue they could generate from LCFS, and estimated reductions in greenhouse-gas emissions.
PG&Es Business EV Rate
This year, PG&E launched its new Business EV Rate to support charging needs for businesses and public agencies, as well as apartment buildings and other public locations. On average, EV customers on the new rate can save up to 40% on charging costs compared to previous rate options, although actual bill impacts will vary for each customer depending on types of vehicles and charging patterns.
Customers on PG&Es Business EV Rate achieve cost savings through a new feature called a subscription charge, which allows customers to choose the amount of kilowatt power they need for their charging stations, similar to choosing a data plan for a phone bill. This subscription charge can be much lower than current rate options, and allows customers to have simpler, more consistent monthly costs.
On the Business EV Rate, customers pay for the electricity used by the EV chargers and the monthly subscription charge. Customers can always adjust their subscription levels up or down to meet their changing needs for EV charging.
Access to more affordable rates and greater bill certainty will help innovative California businesses make new investments in EV charging infrastructure and expand their EV fleets. Learn more at pge.com/businessevrate
PG&Es EV Fleet Program
PG&Es EV Fleet program helps customers with medium-duty, heavy-duty and off-road fleets begin to transition their fleet vehicles to clean electricity to save money, eliminate tailpipe emissions and simplify maintenance. By 2024, the program aims to help more than 700 organizations deploy more than 6,500 EVs across numerous medium- and heavy-duty fleet categories.
Through the EV Fleet program, PG&E builds the electrical infrastructure for customers medium- to heavy-duty EVs from the utility pole (electric service) to the customer meter or to the charger depending on which ownership option the customer chooses. PG&E comprehensively helps customers across all facets of EV charging including available incentives and rebates, site design and permitting, construction and activation, and maintenance and upgrades.
Customers are encouraged to reach out to PG&E early as they consider electrifying their fleets. Customers can submit an interest form and learn more at pge.com/evfleet.
PG&E Ongoing Support for EV Customers
Today, approximately 303,000 EVs are registered in PG&Es service area “ roughly one in every five EVs in the nation. PG&E continues to make it easier for customers to consider EVs through special rates, a total cost of ownership tool, and rebates, as well as the construction of a charging infrastructure through its EV Charge Network, EV Fleet and EV Fast Charge programs. These programs are each working toward the states larger goals of 250,000 charging stations, including 10,000 fast chargers, and 200 hydrogen fueling stations statewide by 2025.
To learn more about PG&Es support for customers with EVs, rates for EV drivers and other resources, visit pge.com/ev.
Pacific Gas and Electric Company, a subsidiary of PG&E Corporation (NYSE:PCG), is one of the largest combined natural gas and electric energy companies in the United States. Based in San Francisco, with more than 23,000 employees, the company delivers some of the nation’s cleanest energy to 16 million people in Northern and Central California. For more information, visit pge.com and pge.com/news.
Long-Term Damage Happening to Canada’s Airlines: CUPE
Monday’s financial update from Ottawa provided no support for Canada’s struggling airlines. CUPE local 4070 represents 4,100 cabin crew members...
To Help Fleet Customers Make the Switch to Electric Vehicles, PG&E Introduces EV Fleet Savings Calculator
Today, Pacific Gas and Electric Company (PG&E) announced a new online tool for companies and organizations considering transitioning their fleets...
Protegrity Partners With Servian, Expanding Global Reach in Australia and New Zealand
Protegrity, the data-security solutions provider, has partnered with Servian, one of Australias leading IT consultancies, to deliver effective data protection...
KBRA Releases Research – 2020 Atlantic Hurricane Season the Stormiest on Record
Kroll Bond Rating Agency (KBRA) releases research on the 2020 Atlantic hurricane season, which officially ended on November 30. KBRA...
Summit Bank Recognized as Top Small Business Administration (SBA) Community Bank Lender in Oregon
Results are in for U.S. Small Business Administration (SBA) loans in Oregon, and Summit Bank (OTC Pink: SBKO) continues to...
Peiffer Wolf: As Holiday Home DNA Kit Bombshells Loom, Here Are the 6 Things Every Potential Victim of “Baby God”-like Fertility Fraud Needs to Know
With the holiday gift-giving season just weeks away, families should be prepared for potentially major shock waves if there are...
Ceramic Market Procurement Report | Roadmap to Recovery for Businesses from the Impact of COVID-19 Pandemic | SpendEdge
The new Ceramic market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact...
Amicalola EMC Partners with ETC to Help Bridge the State’s Digital Divide
Efforts to provide broadband in unserved areas of Georgia have taken another big step forward with a joint announcement in...
Steele Expands Industry-Leading Risk Data & Insights Platform Through info4c Acquisition
Steele Compliance Solutions, Inc., the global leader in ethics and compliance management for the worlds largest multinational enterprises and financial...
KBRA Assigns Preliminary Ratings to ABPCI Direct Lending Fund ABS I Ltd
Kroll Bond Rating Agency (KBRA) assigns preliminary ratings to two classes of notes issued by ABPCI Direct Lending Fund ABS...